118 results about "Parenteral nutrition" patented technology

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.

Materials and methods for preparing and using All-in-One (“AIO”) formulations suitable for administration to infants and neonates for total parenteral nutrition are provided.

A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D₉₀ particle size not greater than about 3 μm; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.

The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.

The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.

The invention discloses the novel combined coenzyme Q10 parenteral solution, mainly containing the coenzyme Q10 as active component, polyethylene glycol 15-hydroxyl stearate as solubilizing agent and water for injection as solvent. One or more solvents of cosolvent, acidity regulator, osmoregulator and stabilizing agents can be also added. Low hemolyzation, extreme low histamine release and higher physiological tolerance of a novel solubilizing agent Solutol HS 15 adopted by the parenteral solution remarkably improves clinical medication security and the compliance of a patient; and the parenteral solution has the advantages of good stability, longer period of validity, higher medication convenience for a clinician, better storage and stable transportation, higher security for the clinical medication and better compliance of the patient. The parenteral solution also has the advantages of simple preparation technology, simple and convenient quality control and lower production cost, thereby being beneficial to industrialization production.

Phosphate depletion, a physiological condition commonly seen in certain patient populations, including alcoholics, malnourished, acutely ill patients, patients receiving parenteral nutrition, patients being re-fed after prolonged fasting, and dialysis patients, requires intravenous supplementation when oral repletion is not feasible. This invention provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate, instead of phosphate, for phosphate or pyrophosphate repletion. During hemodialysis or peritoneal dialysis significant removal of phosphate and pyrophosphate occurs. Pyrophosphate depletion predisposes patients to vascular calcification. This invention further provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate or pyrophosphate repletion by addition of pyrophosphate to hemodialysis or peritoneal dialysis solutions.

The present invention relates to structured triglyceride, to parental nutrition emulsions comprising same, and use thereof. In particular, the invention relates to structured triglycerides comprising at least one medium chain C₆-C₁₂ fatty acid and at least one fatty acid selected from the group consisting of long chain C₁₄-C₁₈ or very long chain C₂₀-C₂₂ fatty acids, preferably each fatty acid is present in a predetermined position of the glycerol backbone. The parenteral nutrition emulsions are particularly useful for nourishing preterm-and term-infants, children, critically ill patients, and cancer patients.

Described herein are pharmaceutical compositions adapted for the parenteral administration of macrolide antibiotics, such as triazole-containing and fluoroketolide antibiotics. Also described herein are methods for their use in the treatment of bacterial, protozoal, and other infections.

The invention describes use of an injectable form of Idebenone, suitable for intravenous injection or infusion. The proposed formulation is an oil-in-water emulsion, where Idebenone is associated with the oil droplets.

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Nutritional compositions such as total parenteral nutrition (TPN) compositions and processes of preparing same are disclosed. The advantage of the present invention lies in its ability to tailor TPN composition to the needs of each individual patient. Various components of the TPN composition may be increased, lowered, or removed based on the measurement of concentration of components and/or their metabolites in patient's blood.

Process for producing parenterally administrable cores. The cores are intermediates suitable for manufacturing sustained release preparations. Microcapsules incorporating a core and a shell and pharmaceutical compositions incorporating such cores and microcapsules are also provided.

Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 μl to 3 ml.

The invention belongs to the field of FSMP (foods for special medical purpose) and particularly relates to a total nutrient formula containing marine active substances for FSMP and a preparation method of the total nutrient formula. According to requirements specified in 'general principles of FSMP', the formula is prepared from fine proteins, composite vegetable oil and carbohydrate taken as main raw materials as well as various vitamins and minerals as auxiliary materials by blending. The formula food adopts reasonable nutrient configuration, is easy to digest and absorb, can be taken as a single nutrient source to meet nutritional requirements of people with limited eating and can be also taken as a nutritional supplement before or after an operation of a patient. The food is simple and safe to take, risks caused by the fact that nutrients are infused directly into veins (parenteral nutrition) are reduced, and digestion-absorption functions of the patient can be promoted to play a role.

Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.